Creative Planning Innoviva, Inc. Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Innoviva, Inc. stock. As of the latest transaction made, Creative Planning holds 26,780 shares of INVA stock, worth $506,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,780

Previous 22,111 21.12%

Holding current value

$506,141

Previous $362,000 42.54%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$16.33 - $20.04 $76,244 - $93,566	4,669 Added 21.12%	26,780 $516,000
Q2 2024 Aug 15, 2024	BUY	$14.4 - $16.4 $41,356 - $47,100	2,872 Added 14.93%	22,111 $362,000
Q1 2024 May 10, 2024	BUY	$14.56 - $16.78 $3,945 - $4,547	271 Added 1.43%	19,239 $293,000
Q4 2023 Feb 14, 2024	BUY	$12.32 - $16.27 $17,494 - $23,103	1,420 Added 8.09%	18,968 $304,000
Q3 2023 Nov 16, 2023	BUY	$12.37 - $13.89 $18,023 - $20,237	1,457 Added 9.05%	17,548 $227,000
Q2 2023 Jul 21, 2023	BUY	$11.39 - $13.72 $183,276 - $220,768	16,091 New	16,091 $204,000
Q2 2019 Jul 26, 2019	SELL	$13.1 - $14.95 $456,142 - $520,559	-34,820 Closed	0 $0
Q1 2019 Apr 24, 2019	SELL	$13.69 - $20.06 $22,793 - $33,399	-1,665 Reduced 4.56%	34,820 $489,000
Q4 2018 Feb 01, 2019	SELL	$13.96 - $18.26 $94,997 - $124,259	-6,805 Reduced 15.72%	36,485 $637,000
Q2 2018 Jul 20, 2018	BUY	$13.44 - $17.59 $92,668 - $121,283	6,895 Added 18.94%	43,290 $597,000
Q1 2018 Apr 18, 2018	BUY	$13.8 - $16.99 $292,422 - $360,018	21,190 Added 139.36%	36,395 $607,000
Q3 2017 Oct 17, 2017	BUY	$12.06 - $14.12 $183,372 - $214,694	15,205	15,205 $215,000

Others Institutions Holding INVA

# of Institutions

229

Shares Held

79.2M

Call Options Held

37.6K

Put Options Held

300

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.32B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Innoviva, Inc. Transaction History